For the quarter ending 2025-09-30, BCAX made $45,062K in revenue. -$36,466K in net income. Net profit margin of -80.92%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development-Related Party | 5,817 | 2,932 | ||
| Research and development-Nonrelated Party | 27,158 | 21,866 | ||
| General and administrative | 7,701 | 7,220 | ||
| Total operating expenses | 40,676 | 32,018 | ||
| Loss from operations | -40,676 | -32,018 | ||
| Interest income | 4,386 | 4,682 | ||
| Total other income | 4,386 | 4,682 | ||
| Net loss before income taxes | -36,290 | -27,336 | ||
| Income tax expense | 40 | 52 | ||
| Net loss | -36,330 | -27,388 | ||
| Unrealized loss on investments, net of tax | -136 | - | ||
| Total other comprehensive loss | -136 | - | ||
| Total comprehensive loss | -36,466 | - | ||
| Net loss per share, basic (in usd per share) | -0.67 | -0.5 | ||
| Net loss per share, diluted (in usd per share) | -0.67 | -0.5 | ||
| Weighted-average number common shares outstanding, basic (in shares) | 54,563,864 | 54,539,230 | ||
| Weighted-average number common shares outstanding, diluted (in shares) | 54,563,864 | 54,539,230 | ||
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)